Prelude Therapeutics
Develops small-molecule oncology programs centered on JAK2V617F inhibition and KAT6A degradation.
$5.52
After-hours close+0.06 (+1.04%)
At close$5.47(−13.80%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.16 | — | — |
| Aug 2026 | −$0.20 | −$0.14 | +28.8% |
| May 2026 | −$0.27 | −$0.13 | +51.9% |
| Mar 2026 | −$0.33 | −$0.20 | +39.4% |
| Nov 2025 | −$0.35 | −$0.26 | +25.7% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.16 | — | — | $35.3M | — | — |
| Aug 11, 2026 | −$0.20 | −$0.14 | +28.8% | $5.7M | $5.7M | 0.0% |
| May 12, 2026 | −$0.27 | −$0.13 | +51.9% | $4.6M | $4.6M | 0.0% |
| Mar 10, 2026 | −$0.33 | −$0.20 | +39.4% | $20.5M | $5.6M | −72.7% |
| Nov 12, 2025 | −$0.35 | −$0.26 | +25.7% | $20.5M | $6.5M | −68.3% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 14, 2025 | ||||||
| May 6, 2025 | ||||||
| Mar 10, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 7, 2024 | ||||||
| Feb 15, 2024 | ||||||
| Nov 1, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 8, 2023 | ||||||
| Mar 15, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 10, 2022 | ||||||
| Mar 16, 2022 | ||||||
| Nov 12, 2021 | ||||||
| Aug 12, 2021 | ||||||
| May 11, 2021 | ||||||
| Mar 16, 2021 | ||||||
| Nov 10, 2020 | ||||||
| Sep 25, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||